Jump to content

Imalumab

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Natureium (talk | contribs) at 18:29, 3 January 2017 (removed Category:Experimental drugs; added Category:Experimental cancer drugs using HotCat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Imalumab (BAX69) is a monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth.[1][2] Phase I studies were completed in early 2016,[3] and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer.[4] It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.[5]

A phase I/II trial in patients with malignant ascites was terminated in 2016.[6]

References

  1. ^ http://mct.aacrjournals.org/content/14/12_Supplement_2/A153
  2. ^ https://www.clinicaltrials.gov/ct2/show/NCT02448810
  3. ^ https://clinicaltrials.gov/show/NCT01765790
  4. ^ https://www.clinicaltrials.gov/ct2/show/NCT02448810
  5. ^ http://adisinsight.springer.com/drugs/800010225
  6. ^ http://adisinsight.springer.com/drugs/800010225
Retrieved from "https://en.wikipedia.org/w/index.php?title=Imalumab&oldid=758139273"